NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Ascending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
71288-0166-91 | 71288-0166 | Pemetrexed disodium | Pemetrexed | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
71288-0166-92 | 71288-0166 | Pemetrexed disodium | Pemetrexed | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
71288-0167-50 | 71288-0167 | Pemetrexed disodium | Pemetrexed | 500.0 mg/50mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
71288-0167-95 | 71288-0167 | Pemetrexed disodium | Pemetrexed | 500.0 mg/50mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
72606-0011-01 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | April 3, 2023 | In Use | |
72606-0011-10 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | April 3, 2023 | In Use | |
72606-0012-01 | 72606-0012 | Bevacizumab-adcd | Vegzelma | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | April 3, 2023 | In Use | |
72606-0012-10 | 72606-0012 | Bevacizumab-adcd | Vegzelma | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | April 3, 2023 | In Use | |
72819-0152-95 | 72819-0152 | Mitomycin | Mitomycin | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | March 11, 2022 | In Use | |
72819-0152-05 | 72819-0152 | Mitomycin | Mitomycin | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | April 25, 2022 | In Use | |
72819-0153-02 | 72819-0153 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | April 25, 2022 | In Use | |
72819-0154-04 | 72819-0154 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | April 25, 2022 | In Use | |
80978-0111-06 | 80978-0111 | Nelarabine injection | NELARABINE | 250.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | April 12, 2023 | In Use | |
81927-0111-01 | 81927-0111 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | March 15, 2023 | In Use | |
81927-0111-06 | 81927-0111 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | March 15, 2023 | In Use | |
00069-1311-04 | 00069-1311 | epoetin alfa-epbx | RETACRIT | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Dec. 1, 2020 | In Use | ||
00069-1311-10 | 00069-1311 | epoetin alfa-epbx | RETACRIT | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Nov. 9, 2020 | In Use | ||
00002-7623-01 | 00002-7623 | Pemetrexed disodium | Alimta | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Feb. 13, 2004 | In Use | |
00002-7623-61 | 00002-7623 | Pemetrexed disodium | Alimta | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | July 24, 2012 | March 30, 2015 | In Use |
00024-5840-01 | 00024-5840 | ziv-Aflibercept | Zaltrap | 100.0 mg/4mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug. 3, 2012 | In Use | |
00024-5840-03 | 00024-5840 | ziv-Aflibercept | Zaltrap | 100.0 mg/4mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug. 3, 2012 | Nov. 27, 2019 | In Use |
00024-5841-01 | 00024-5841 | ziv-Aflibercept | Zaltrap | 200.0 mg/8mL, 200.0 mg/8mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug. 3, 2012 | In Use | |
00069-1305-10 | 00069-1305 | epoetin alfa-epbx | RETACRIT | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 18, 2018 | In Use | ||
00069-1307-10 | 00069-1307 | epoetin alfa-epbx | RETACRIT | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 18, 2018 | In Use | ||
00069-1308-10 | 00069-1308 | epoetin alfa-epbx | RETACRIT | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 18, 2018 | In Use |
Found 10,000 results in 5 milliseconds — Export these results